Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab A/S    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
Delayed Quote. Delayed NASDAQ OMX COPENHAGEN - 11/27 10:59:53 am
2319 DKK   +0.52%
11/25NOVARTIS : Genmab Announces Enapotamab Vedotin Update
AQ
11/24GENMAB A/S : Announces Enapotamab Vedotin Update
AQ
11/24GENMAB A/S : Announces Enapotamab Vedotin Update
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Genmab A/S : The underlying trend is to the upside

06/15/2020 | 08:09am EST
06/15/2020 | 08:09am EST
long trade
Target price hit
Entry price : 2011DKK | Target : 2200DKK | Stop-loss : 1800DKK | Potential : 9.4%
Shares in Genmab A/S show a positive technical chart pattern over the medium term. The timing to jump back on the rising trend seems good.
Investors have an opportunity to buy the stock and target the DKK 2200.
Genmab A/S : Genmab A/S : The underlying trend is to the upside
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

Strengths
  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Historically, the company has been releasing figures that are above expectations.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
  • For the past twelve months, EPS forecast has been revised upwards.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 1538 DKK

Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • The stock is close to a major daily resistance at DKK 2101, which should be gotten rid of so as to gain new appreciation potential.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the past year, analysts have significantly revised downwards their profit estimates.

© Zonebourse.com 2020
Stocks mentioned in the article
ChangeLast1st jan.
AMP LIMITED 0.00% 1.73 End-of-day quote.-9.66%
GENMAB A/S 0.52% 2319 Delayed Quote.56.53%

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2020 9 830 M 1 581 M 1 581 M
Net income 2020 4 665 M 750 M 750 M
Net cash 2020 15 033 M 2 418 M 2 418 M
P/E ratio 2020 32,3x
Yield 2020 -
Capitalization 152 B 24 374 M 24 396 M
EV / Sales 2020 13,9x
EV / Sales 2021 16,9x
Nbr of Employees 712
Free-Float 95,2%
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 2 194,34 DKK
Last Close Price 2 319,00 DKK
Spread / Highest target 29,4%
Spread / Average Target -5,38%
Spread / Lowest Target -90,2%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Deirdre P. Connelly Chairman
Anthony Mancini Chief Operating Officer & Executive Vice President
Anthony Pagano Chief Financial Officer & Executive Vice President
Michael K. Bauer SVP, Head-Operations, Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB A/S56.53%24 374
WUXI APPTEC CO., LTD.56.53%37 916
BEIGENE, LTD.72.47%26 060
NEUROCRINE BIOSCIENCES, INC.-11.51%8 928
SPRINGWORKS THERAPEUTICS, INC.76.67%3 259
AXSOME THERAPEUTICS, INC.-27.26%2 808